Problem being addressed[edit | edit source]

Gestational diabetes mellitus (GDM) occurs due to uncontrollable levels of blood glucose with onset or first recognition during pregnancy. This can cause several serious health problems for both mother and child, including the predisposition of Type 2 diabetes. The current tests in place to regulate glucose levels often demand fasting and multiple hours to complete, leading to low patient compliance.

Detailed description of the solution[edit | edit source]

The Rapid Strip Assay (RDT) is meant to identify a new biomarker, glycated albumin, which can diagnose GDM within several minutes. This allows a cheaper and faster method to determine if pregnant mothers or their babies will develop diabetes. Following the test, patients can be counseled on diet, exercise, further screening, or insulin ingestion based on the test results.

Designed by[edit | edit source]

  • Designed by: PATH, University of Washington Laboratory of Medicine
  • Manufacturer location: Seattle, Washington USA, India

When and where it was tested/implemented[edit | edit source]

Project from 2011-2013, Seattle, WA USA and India

Funding Source[edit | edit source]

Health Innovation Portfolio, The Saving Life at Birth Consortium, Madras Diabetes Research Foundation

References[edit | edit source]

Other internally generated reports[edit | edit source]

Path. Gestational Diabetes. Retrieved November 13 2013 from here.

Path. (July 2012). Rapid screening test for gestational diabetes. Retrieved November 13 2013 from here.

Externally generated reports[edit | edit source]

Saving Lives at Birth. (2011). Strip test for glycated albumin screening. Retrieved November 13 2013 from here.

Discussion[View | Edit]

Cookies help us deliver our services. By using our services, you agree to our use of cookies.